Crispr-cas-based novel guide ran capable of specific detection of norovirus GII.4 and application thereof

A novel guide RNA specific to norovirus GII.4, used in conjunction with CRISPR-Cas proteins and RPA, addresses the sensitivity and specificity issues of existing detection methods, enabling accurate and rapid detection of norovirus GII.4 in biological samples.

WO2024232476A1PCT designated stage expired Publication Date: 2024-11-14PULMUONE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/012181
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2023-08-17
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current methods for detecting norovirus GII.4, such as commercial enzyme immunoassays and RT-PCR, face challenges with sensitivity and specificity, and CRISPR-Cas-based platforms have not effectively detected norovirus GII.4 with high specificity.

Method used

Development of a novel guide RNA specific to norovirus GII.4, combined with CRISPR-Cas proteins, for amplifying and detecting the virus using recombinase polymerase amplification (RPA) and subsequent CRISPR gene editing reactions, enabling sensitive and specific detection.

Benefits of technology

The guide RNA enables highly sensitive and specific detection of norovirus GII.4, improving the accuracy of infectious disease diagnosis and food poisoning diagnosis, with the ability to quickly detect the virus in biological samples.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023012181_14112024_PF_FP_ABST
    Figure KR2023012181_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a CRISPR-Cas-based novel guide RNA capable of specific detection of norovirus GII.4 and a method for, by using same, the detection of norovirus GII.4 and the diagnosis of infection thereby. Using the guide RAN provided by the present invention, norovirus GII.4 in specimens can be rapidly detected with very high sensitivity and specificity.
Need to check novelty before this filing date? Find Prior Art

Description

A novel guide RNA capable of detecting norovirus GII.4 specifically based on CRISPR-CAS and its application.

[0001] This application claims the benefit of Republic of Korea Patent Application No. 10-2023-0059731, filed on May 9, 2023, the entire disclosure of which is incorporated herein by reference.

[0002]

[0003] The present invention relates to a novel guide RNA capable of detecting norovirus GII.4 specifically based on CRISPR-Cas and a method for detecting norovirus GII.4 and diagnosing infection thereof using the same.

[0004]

[0005] Norovirus is known worldwide as a cause of nonbacterial acute gastroenteritis, and is a type of enteric virus that causes infectious gastroenteritis in humans when contaminated food or water is consumed. Norovirus belongs to the family Calicivirdae and has a single-stranded RNA genome of 7.5 to 7.5 kb in size, consisting of three open reading frames (ORFs). Norovirus was first discovered in 1968 from the diarrheal stool of a patient with mass food poisoning at Norwalk Elementary School in Norwalk, Ohio, and was called (Norwalk Viruses) at the time. In August 2002, the International Committee on Taxonomy of Viruses (ICTV) unified the name to norovirus. Currently, among the five types of norovirus (GI, GII, GIII, GIV, GV) classified by genotype, the genotypes that cause infection in humans are the GI, GII, and GIV groups. Among them, genotype GII.4 is involved in most norovirus food poisoning cases worldwide, and in Korea, GII.3 has been reported to have a high detection rate following GII.4.

[0006]

[0007] If you are infected with norovirus, the main symptoms are nausea, vomiting, diarrhea, and abdominal pain. In most cases, symptoms are mild and recover naturally after 1-2 days. The incubation period is 24-48 hours, and the virus can enter the mouth through contaminating food or water with the virus in the stool or vomit of an infected person, or through eating, drinking, or touching contaminated objects or food that the infected person has touched. It is easily transmitted, so even a small amount of the virus can cause infection, and contagiousness is most severe during the onset of symptoms and lasts from 3 days to up to 2 weeks after recovery (Korea Centers for Disease Control and Prevention Health Information).

[0008]

[0009] Although commercial enzyme immunoassay (EIA) diagnostic kits for detecting norovirus antigens have been developed, the EIA analysis method has the disadvantage of varying sensitivity depending on the norovirus strain. Therefore, although it can be used as an auxiliary means in identifying the cause of an outbreak caused by norovirus, it has been reported to have technical limitations for use as a standard protocol for diagnosis. Generally, reverse transcription polymerase chain reaction (RT-PCR) and real-time RT-PCR methods, which directly amplify and detect viral genes from the patient's stool, are widely used for detection and diagnosis. However, they have the disadvantage of requiring high costs for primer or probe production because it is difficult to detect with high sensitivity with a single primer pair.

[0010]

[0011] Recently, CRISPR-Cas-based DNA detection platforms, including SHERLOCK (Cas13), DETECTR (Cas12a), and Cas14-DETECTR, with high detection sensitivity and specificity have been developed, but no related technology has been developed yet that can detect norovirus GII.4 with very high specificity.

[0012]

[0013] Therefore, to improve the accuracy and sensitivity of accurate detection of norovirus GII.4 and diagnosis of its infection, it is necessary to develop a novel guide RNA and a method using the same for use in a CRISPR-Cas-based gene detection method.

[0014]

[0015] Accordingly, the inventors of the present invention developed a novel guide RNA capable of specifically detecting norovirus GII.4 together with a CRISPR-Cas protein and evaluated its effectiveness, thereby completing the present invention.

[0016]

[0017] Accordingly, an object of the present invention is to provide a norovirus GII.4 specific guide RNA comprising the base sequence of sequence number 1.

[0018]

[0019] Another object of the present invention is to provide a composition and kit for detecting norovirus GII.4 comprising the guide RNA.

[0020] In addition, another object of the present invention is to provide a composition and kit for detecting norovirus GII.4 comprising the guide RNA.

[0021] In addition, another object of the present invention is to provide a composition and kit for detecting norovirus GII.4, which essentially consists of the guide RNA.

[0022]

[0023] Another object of the present invention is to provide a method for detecting norovirus GII.4 comprising the following steps:

[0024] (a) a step of amplifying nucleic acid obtained from a sample;

[0025] (b) a step of adding the guide RNA, endonuclease, and reporter gene to the amplification product and reacting them; and

[0026] (c) A step of detecting a signal of the reporter gene.

[0027]

[0028] Another object of the present invention is to provide a composition for diagnosing food poisoning comprising the guide RNA.

[0029] In addition, another object of the present invention is to provide a composition for diagnosing food poisoning comprising the guide RNA.

[0030] In addition, another object of the present invention is to provide a composition for diagnosing food poisoning essentially consisting of the guide RNA.

[0031]

[0032] Another object of the present invention is to provide a use of the guide RNA for preparing a composition for diagnosing food poisoning.

[0033]

[0034] Another object of the present invention is to provide a method for diagnosing food poisoning comprising the following steps:

[0035] (a) a step of amplifying nucleic acid obtained from a sample;

[0036] (b) a step of adding the guide RNA, endonuclease, and reporter gene to the amplification product and reacting them;

[0037] (c) detecting a signal of the reporter gene; and

[0038] (d) A step of diagnosing food poisoning when a signal of the reporter gene of step (c) is detected.

[0039]

[0040] However, the aforementioned tasks of the present invention are exemplary and do not limit the scope of the present invention. Furthermore, other objectives and advantages of the present invention will become more apparent through the detailed description, claims, and drawings below.

[0041]

[0042] In order to achieve the above-described purpose of the present invention, the present invention provides a norovirus GII.4 specific guide RNA comprising the base sequence of sequence number 1.

[0043]

[0044] In order to achieve another object of the present invention, the present invention provides a composition and kit for detecting norovirus GII.4 comprising the guide RNA.

[0045] In addition, in order to achieve another object of the present invention, the present invention provides a composition and kit for detecting norovirus GII.3 comprising the guide RNA.

[0046] In addition, in order to achieve another object of the present invention, the present invention provides a composition and kit for detecting norovirus GII.3, which essentially consists of the guide RNA.

[0047]

[0048] In order to achieve another object of the present invention, the present invention provides a method for detecting norovirus GII.4 comprising the following steps:

[0049] (a) a step of amplifying nucleic acid obtained from a sample;

[0050] (b) a step of adding the guide RNA, endonuclease, and reporter gene to the amplification product and reacting them; and

[0051] (c) A step of detecting a signal of the reporter gene.

[0052]

[0053] In order to achieve another object of the present invention, the present invention provides a composition for diagnosing food poisoning comprising the guide RNA.

[0054] In addition, in order to achieve another object of the present invention, the present invention provides a composition for diagnosing food poisoning comprising the guide RNA.

[0055] In addition, in order to achieve another object of the present invention, the present invention provides a composition for diagnosing food poisoning essentially consisting of the guide RNA.

[0056]

[0057] In order to achieve another object of the present invention, the present invention provides a use of the guide RNA for preparing a composition for diagnosing food poisoning.

[0058]

[0059] In order to achieve another object of the present invention, the present invention provides a method for diagnosing food poisoning comprising the following steps:

[0060] (a) a step of amplifying nucleic acid obtained from a sample;

[0061] (b) a step of adding the guide RNA, endonuclease, and reporter gene to the amplification product and reacting them;

[0062] (c) detecting a signal of the reporter gene; and

[0063] (d) A step of diagnosing food poisoning when a signal of the reporter gene of step (c) is detected.

[0064]

[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0066]

[0067] The present invention is described in detail below.

[0068]

[0069] The present invention provides a norovirus GII.4 specific guide RNA comprising the base sequence of sequence number 1.

[0070]

[0071] In the present invention, the guide RNA may be crRNA or gRNA. crRNA is called CRISPR RNA. In addition, gRNA refers to guide RNA. crRNA and gRNA may be single-stranded RNA. In addition, crRNA can bind to tracrRNA to activate a CRISPR-associated protein, and crRNA can be used in a form bound to tracrRNA. In this case, crRNA may have a sequence complementary to a gene sequence specifically present in norovirus GII.4. In addition, gRNA can also bind to a gene sequence specifically present in norovirus GII.4 to activate a CRISPR-associated protein. The crRNA or gRNA may be RNA composed of 15 to 40 nucleic acids. In one specific example, the crRNA or gRNA may be composed of 24 nucleic acids. Additionally, the crRNA or gRNA may include additional sequences (e.g., tracrRNA, scoutRNA) at the 3' end to activate a CRISPR-associated protein such as Cas12, Cas13, or Cas14. The guide RNA may include a polynucleotide complementary to a nucleotide sequence of 2 to 24 consecutive nucleotides (e.g., about 20 nt) (hereinafter referred to as “nt”) in the 5' or 3' direction of the PAM in the target nucleic acid. The length of the guide RNA may be 10 nt to 100 nt, 10 nt to 90 nt, 10 nt to 80 nt, 10 nt to 70 nt, 10 nt to 60 nt, 10 nt to 50 nt, 15 nt to 50 nt, 20 nt to 50 nt, 25 nt to 50 nt, 30 nt to 50 nt, 35 nt to 50 nt, 40 nt to 50 nt, or 45 nt to 50 nt. In one embodiment, the gRNA may be characterized by including the base sequence of SEQ ID NO: 1.

[0072]

[0073] The present invention also provides a composition for detecting norovirus GII.4 comprising the guide RNA.

[0074]

[0075] The composition according to the present invention may further include additional components for specifically detecting norovirus GII.4 using the guide RNA, specifically, an endonuclease and a reporter gene, and may further include a primer pair capable of amplifying the norovirus GII.4 gene by including a sequence complementary to the same.

[0076]

[0077] In the present invention, the term "primer" means a short nucleic acid sequence having a short free 3' hydroxyl group, which can form base pairs with a complementary template of a norovirus nucleic acid, and which functions as a starting point for template strand copying. The composition according to the present invention may include any primer pair having a sequence complementary to the gene of norovirus GII.4 and capable of amplifying it, and preferably, the primer pair may be one capable of specifically amplifying the VP1 capsid region of the ORF2 gene of norovirus GII.4.

[0078]

[0079] In one embodiment of the present invention, the primer pair may include a forward primer comprising a base sequence selected from the group consisting of SEQ ID NOs: 2 to 6 and a reverse primer comprising a base sequence of SEQ ID NO: 7, preferably a forward primer comprising a base sequence of SEQ ID NO: 5 and a reverse primer comprising a base sequence of SEQ ID NO: 7, and most preferably a forward primer comprising a base sequence of SEQ ID NO: 5 and a reverse primer comprising a base sequence of SEQ ID NO: 7. The forward primer selected from the group consisting of SEQ ID NOs: 2 to 6 and the reverse primer of SEQ ID NO: 7 specifically amplify the VP1 capsid region of the ORF2 gene of norovirus GII.4, and norovirus GII.4 can be detected by analyzing the amplification product.

[0080]

[0081] The above amplification can be performed by any method used in the art to amplify an amplification target (gene, etc.), and for example, can be performed by recombinase polymerase amplification (RPA), but is not limited thereto.

[0082]

[0083] The amplification product may be, for example, an amplicon, but is not limited thereto.

[0084]

[0085] In this specification, the term "Recombinase Polymerase Amplification (RPA)" refers to a technology that can confirm DNA and RNA amplification. Unlike conventional PCR, it is a technology that can amplify target sequences quickly and accurately using DNA binding proteins and recombinase. RPA is similar to the conventional PCR method, but it has the advantage of shortening the reaction time because it can amplify specific genes at a constant temperature without temperature change, and it has the advantage of low testing cost because it does not require special equipment, and it has excellent transportability, so it can be tested on site. Recombinase Polymerase Amplification (RPA) is a method that causes dissociation of DNA double strands using bacteriophage T4 recombinase and simultaneously amplifies specific DNA using DNA polymerase and specific primers. Like PCR, it can amplify DNA of a specific base sequence using a target template and a pair of primers (oligonucleotides), but unlike PCR, it has the advantage of being able to cause an amplification reaction under isothermal conditions within a certain temperature range (37℃ - 42℃). Currently, RPA has been developed to produce amplified products very quickly, and this, along with the advantage of isothermal conditions, is widely recognized, and RPA is being applied in various ways to detect specific pathogens through specific gene amplification.

[0086]

[0087] It is recommended that the length of the RPA amplification product does not exceed 500 nt (nucleotides), and the amplification product length is generally between 100 and 250 nt. Unlike PCR, the primer length for RPA is recommended to be at least 30 nucleotides, and the length is generally 32 to 35 nt. In addition, since it is not sensitive to the sequence GC ratio (GC%) and Tm (melting temperature) value like PCR, the RPA primer should converge to GC% (20 to 70%) and Tm (50 to 100℃) (Analyst, 2019, 144, 31).

[0088]

[0089] In the present invention, the endonuclease may be a CRISPR-associated protein. The term "CRISPR-associated protein," as used herein, refers to an enzyme capable of recognizing and cleaving double-stranded or single-stranded nucleic acids, such as DNA or RNA (dsDNA / RNA and ssDNA / RNA). Specifically, they can recognize and cleave double-stranded or single-stranded nucleic acids bound to crRNA or gRNA.

[0090]

[0091] In the present invention, one specific example of the endonuclease may be one that recognizes that the gRNA has bound to the target site and thus has endonuclease function activated. Furthermore, upon activation of the endonuclease function, the endonuclease may possess exonuclease activity capable of non-specifically cleaving double-stranded and / or single-stranded DNA and / or RNA. Furthermore, CRISPR-associated proteins, such as Cas12, Cas13, or Cas14, once activated, may exhibit non-specific exonuclease activity. This may involve cleaving the target nucleic acid to which the guide RNA is bound (cis-cleavage) or non-specifically cleaving any external nucleic acid, specifically, reporter nucleic acid (DNA and / or RNA) (trans-cleavage).

[0092]

[0093] Accordingly, in one specific example of the composition of the present invention, crRNA or gRNA is bound to a specific target site of norovirus GII.4, and the reporter is cleaved by a non-specific nuclease activated thereby, thereby enabling detection of norovirus GII.4 by emission of a fluorescent substance bound to the reporter.

[0094]

[0095] Specifically, one specific example of the CRISPR-associated protein may be Cas12, Cas13 or Cas14, and specifically any one selected from the group consisting of Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas13a, Cas13b, Cas13c, Cas13d and Cas14.

[0096]

[0097] The above Cas12 and Cas14 can cleave ssDNA of any sequence or dsDNA of the target nucleic acid by exhibiting endonuclease activity and non-specific exonuclease activity in the presence or absence of a PAM sequence in the target nucleic acid after binding to a guide RNA complementary to the target nucleic acid.

[0098] The above Cas13 can cleave ssRNA of any sequence or ssRNA of the target nucleic acid after binding to a guide RNA complementary to the target nucleic acid.

[0099]

[0100] Since the region within the gene of norovirus GII.4 to which the guide RNA according to the present invention complementarily binds contains a TTTG PAM sequence, the present invention can be applied in combination with a CRISPR-associated protein that requires a PAM sequence of (T)TTV, TTN, TN, or TG to exhibit endonuclease or exonuclease activity, or does not require a PAM sequence.

[0101]

[0102] In the present invention, the reporter gene refers to any sequence of DNA or RNA that is cleaved by the exonuclease activity of a CRISPR-associated protein, and it is preferable that the reporter gene is labeled with a detectable label. The detectable label may be bound to the end or inside of the reporter gene. The detectable label may be a chemical label, an enzymatic label, a radioactive label, a fluorescent label, a luminescent label, a chemiluminescent label, a FRET (fluorescence resonance energy transfer) label, a metal label, or a combination thereof. The fluorescent label may be selected from the group consisting of FAM, TET, JOE, YAKYE, HEX, CY3, ATTO550, TAM, ROX, TxRed, CY35, LC610, LC640, ATTO647N, CY5, VIC, evergreen dye, and ATTO680, but is not limited thereto.

[0103]

[0104] In one aspect of the present invention, the composition may be characterized as being used in a method for detecting norovirus GII.4 by an isothermal amplification reaction and a subsequent CRISPR gene scissors reaction.

[0105]

[0106] Specifically, if a target region exists in the amplified product amplified by a primer pair capable of amplifying the norovirus GII.4 gene, preferably a primer pair capable of specifically amplifying the VP1 capsid region of the ORF2 gene of norovirus GII.4, the guide RNA complementarily binds to the target region, and an endonuclease, preferably a CRISPR-associated protein, is activated to cut the sequence of the reporter gene. As a result, norovirus GII.4 can be detected by a label bound to the reporter gene.

[0107]

[0108] The present invention also provides a kit for detecting norovirus GII.4 comprising the composition.

[0109]

[0110] The above kit may be a kit containing the essential elements necessary for performing the detection of norovirus GII.4, and may include, in addition to the composition, a test tube or other suitable container, a reaction buffer (with various pH and magnesium concentrations), deoxynucleotides (dNTPs), an enzyme such as Taq polymerase, DNase, RNAse inhibitor, DEPC water, and sterile water.

[0111]

[0112] The present invention also provides a method for detecting norovirus GII.4, comprising the following steps:

[0113] (a) a step of amplifying nucleic acid obtained from a sample;

[0114] (b) a step of reacting by adding the guide RNA, endonuclease and reporter gene according to claim 1 to the amplification product; and

[0115] (c) A step of detecting a signal of the reporter gene.

[0116]

[0117] In the present invention, the “specimen” refers to a substance or organism used for testing, inspection, analysis, etc., and its type is not particularly limited, but may be a food or biological sample suspected of having norovirus GII.4. The specimen may be a patient in need of the above treatment effect.

[0118]

[0119]

[0120] In the present invention, the biological sample is obtained by separating from a specimen suspected of having a disease, and may include, but is not limited to, tissue, cells, whole blood, serum, plasma, cerebrospinal fluid, colostrum, synovial fluid, saliva, feces, cell culture supernatant, etc.

[0121]

[0122] Nucleic acids can be obtained from a sample using conventional nucleic acid extraction methods. If the starting material is gDNA, gDNA isolation can be performed using conventional methods known in the art. If the starting material is mRNA, cDNA can be synthesized using reverse transcriptase. For example, RNA isolation is not particularly limited as long as it is a method commonly used to isolate RNA from a sample. For example, commercially available RNA isolation kits, such as Qiagen's RNeasy mini kit, can be used.

[0123]

[0124] In the present invention, the “amplification” may be one selected from the group consisting of PCR, RT (reverse transcription)-PCR, isothermal amplification (RPA) and RT (reverse transcription)-RPA, preferably RPA or RT-RPA, and most preferably RT-RPA.

[0125]

[0126] The above “isothermal amplification” refers to a method of amplifying a target nucleic acid sequence (template) under a constant reaction temperature condition, and may be any one of recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), rolling circle amplification (RCA), multiple displacement amplification (MDA), strand displacement amplification (SDA), and nucleic acid sequence-based amplification (NASBA), and preferably recombinase polymerase amplification (RPA).

[0127]

[0128] Detection of the above amplification product can be performed through, but is not limited to, capillary electrophoresis, DNA chip, gel electrophoresis, radiometric measurement, fluorescence measurement, or phosphorescence measurement.

[0129]

[0130] As one method of detecting an amplification product, for example, capillary electrophoresis can be performed. Capillary electrophoresis can be performed, for example, using ABi Sequencer. In addition, gel electrophoresis can be performed, and agarose gel electrophoresis or acrylamide gel electrophoresis can be used depending on the size of the amplification product. In addition, a fluorescence measurement method is performed by labeling the 5'-end of a primer with Cy-5 or Cy-3, and when PCR is performed, the target sequence is labeled with a detectable fluorescent label, and the fluorescence of the labeled substance can be measured using a fluorometer. In addition, a radioactivity measurement method is performed by adding a radioactive isotope such as 32P or 35S to the PCR reaction solution during PCR to label the amplification product, and then measuring the radioactivity using a radiometric measuring device such as a Geiger counter or a liquid scintillation counter. In addition, the RPA amplification product can be obtained and separated by a method such as agarose gel electrophoresis, and the presence of DNA having a length corresponding to the DNA polymerized by the primer set used, specifically, a length of 151 bp, can be confirmed to detect norovirus GII.4.

[0131]

[0132] In one aspect of the present invention, when the endonuclease is Cas13, a step of transcribing the amplification product of step (a) may be additionally performed.

[0133]

[0134] Specific examples of detecting norovirus GII.4 using the method of the present invention are as follows:

[0135] (1) The gene of norovirus GII.4 present in the specimen is amplified using a primer pair. If the gene is DNA, the gene is amplified by PCR, RPA, etc., and if the gene is RNA, the gene is amplified by RT (reverse transcription)-PCR, RT-RPA, etc.

[0136] (2) In the case of Cas13, the amplification product is further transcribed (e.g., T7 transcription) and converted into RNA, while Cas12 and Cas14 use the amplification product of (1) as is.

[0137] (3) The guide RNA, Cas12 or Cas14, and reporter DNA are mixed with the amplification product of the above (1), or the guide RNA, Cas13, and reporter RNA are mixed with the amplification product transcript of the above (2) and reacted.

[0138] (4) The signal generated by the above reporter being cut is detected.

[0139]

[0140] The present invention also provides a composition for diagnosing food poisoning.

[0141]

[0142] The present invention provides a use of the guide RNA for preparing a composition for diagnosing food poisoning.

[0143]

[0144] The present invention provides a method for diagnosing food poisoning comprising the following steps:

[0145] (a) a step of amplifying nucleic acid obtained from a sample;

[0146] (b) a step of adding a guide RNA, endonuclease and reporter gene according to claim 1 to the amplification product and reacting them;

[0147] (c) detecting a signal of the reporter gene; and

[0148] (d) A step of diagnosing food poisoning when a signal of the reporter gene of step (c) is detected.

[0149]

[0150] In one embodiment, the present invention provides a method for diagnosing and treating food poisoning in a specimen, comprising the steps of:

[0151] (i) a step of amplifying nucleic acid obtained from a sample;

[0152] (ii) a step of adding a guide RNA, endonuclease and reporter gene according to claim 1 to the amplification product and reacting them;

[0153] (iii) a step of detecting a signal of the reporter gene;

[0154] (iv) a step of diagnosing food poisoning when a signal of the reporter gene of step (iii) is detected; and

[0155] (v) A step of administering a therapeutic drug to treat food poisoning to the diagnosed specimen or treating the disease through surgery.

[0156]

[0157] The methods comprising steps (i) to (v) are understood to be similar to the methods comprising steps (a) to (d) described above.

[0158]

[0159] The above step (v) is a step for treating the disease by means of administering a therapeutic drug such as ciprofloxacin, azithromycin, or ceftriaxone to a sample diagnosed with the disease in the above step (iv), or by surgery, etc.

[0160]

[0161] The term “diagnosis” as used herein includes determining whether a subject currently has a particular disease or condition, or determining the prognosis of a subject suffering from a particular disease or condition.

[0162]

[0163] The 'treatment' of the present invention comprehensively refers to improving food poisoning or symptoms of food poisoning, which may include curing, substantially preventing, or improving the condition of the disease, and includes, but is not limited to, alleviating, curing, or preventing one or most of the symptoms resulting from the disease.

[0164]

[0165] In this specification, the term “comprising” is used with the same meaning as “including” or “characterized by,” and does not exclude additional components or method steps, etc. that are not specifically mentioned in the composition or method according to the present invention. In addition, the term “consisting of” means excluding additional elements, steps, or components, etc. that are not separately described. The term “essentially consisting of” means that, in the scope of the composition or method, it may include materials or steps, etc. that do not substantially affect the basic characteristics thereof, in addition to the materials or steps described.

[0166]

[0167] The composition comprising the guide RNA provided by the present invention can specifically detect norovirus GII.4, and thus, by using the composition, norovirus GII.4 in a biological sample to be diagnosed (e.g., feces, blood, etc.) can be quickly and accurately detected, and diseases caused by norovirus GII.4 infection, specifically food poisoning, can be diagnosed very quickly and accurately.

[0168]

[0169] Using the guide RNA provided by the present invention, norovirus GII.4 in a sample can be rapidly detected with very high sensitivity and specificity.

[0170]

[0171] Figure 1 is a diagram showing the location and sequence within the gene targeted by gRNA for detection of norovirus GII.4 and the PAM sequence.

[0172]

[0173] Figure 2 is a diagram showing the process and results of constructing a primer pair combination capable of amplifying the gene of norovirus GII.4 with high sensitivity.

[0174]

[0175] Figure 3 shows the experimental conditions for amplifying the gene of norovirus GII.4 using a primer pair and detecting norovirus GII.4 using the amplified product using gRNA, CRISPR-Cas12a (Cpf1) and a reporter gene.

[0176]

[0177] Figure 4 shows the results of confirming the detection sensitivity by amplifying the gene of norovirus GII.4 using a primer pair and detecting norovirus GII.4 using the amplified product using gRNA, CRISPR-Cas12a (Cpf1) and a reporter gene.

[0178]

[0179] Figure 5 shows the results of confirming the detection specificity by detecting various viruses using gRNA according to the present invention (MBC111-R: norovirus GII.3, NCCP76067: norovirus GII.4).

[0180]

[0181] Hereinafter, preferred examples are presented to aid understanding of the present invention. However, the following examples are provided solely to facilitate understanding of the present invention and are not intended to limit the scope of the present invention.

[0182]

[0183] Example 1: Selection of gRNA for detection of norovirus GII.4

[0184] The core of diagnostic research using CRISPR gene scissors technology is the applied Cas protein and gRNA. In this study, cpf1 (Cas12a), which is active on dsDNA, was selected, and the protein is known to require T-rich PAM (TTTV) in the target.

[0185]

[0186] A gRNA specific to GII.4 was selected by aligning the VP1 capsid region of the Norovirus GII ORF2 gene with each reference genome (GII.4: NC_039477) of the GII.4 genotype and each standard pathogen sequence (Fig. 1).

[0187]

[0188] Example 2: RPA primer design

[0189] For the selected gRNA target and optimal RPA primer design, 5 combinations of forward 5 and reverse 1 regions were selected and RPA primer validation targeting Norovirus GII.4 (NCCP 76067) was performed, and the primer pair with the best reaction combination was used in the following experiments (Fig. 2).

[0190]

[0191] Example 3: Detection experiment of norovirus GII.4 using gRNA, primer pair, and CRISPR-Cas12a.

[0192] After amplification of the norovirus GII.4 gene using the final selected primer pair, the gRNA and CRISPR-Cas12a application reactions were performed, and the detailed reaction conditions are shown in Figure 3. The mixture dispensed using the protocol was measured every minute using an isothermal fluorescence detector at 37°C, and the results are shown in Figure 4.

[0193]

[0194] As shown in Figure 4, it was confirmed to exhibit very high detection sensitivity at the 1 copy level.

[0195]

[0196] Example 4: Evaluation of detection specificity

[0197] Detection experiments for various food-related viruses were conducted using the same method as in Example 3 above. As a result, as shown in Fig. 5, no viruses other than norovirus were detected, and furthermore, norovirus GII.3 was not detected either, confirming a very high specificity.

[0198]

[0199] The RNA provided by the present invention can rapidly detect norovirus GII.4 in a sample with very high sensitivity and specificity, and thus has very high potential for industrial application.

Claims

1. Norovirus GII.4 specific guide RNA comprising the base sequence of sequence number 1.

2. A composition for detecting norovirus GII.4 comprising the guide RNA according to paragraph 1.

3. A composition according to claim 2, characterized in that the composition further comprises an endonuclease.

4. A composition according to claim 3, wherein the endonuclease is a CRISPR-associated protein.

5. A composition according to claim 4, characterized in that the CRISPR-associated protein is selected from the group consisting of Cas12, Cas13, and Cas14.

6. A composition according to claim 2, characterized in that the composition further comprises a reporter gene.

7. A composition according to claim 6, characterized in that the reporter gene is labeled with a detectable label.

8. A kit for detecting norovirus GII.4 comprising the guide RNA of paragraph 1.

9. Method for detecting norovirus GII.4 comprising the following steps: (a) a step of amplifying nucleic acid obtained from a sample; (b) a step of reacting by adding the guide RNA, endonuclease and reporter gene according to claim 1 to the amplification product; and (c) A step of detecting a signal of the reporter gene.

10. A detection method according to claim 9, characterized in that the sample is a food or biological sample.

11. A composition for diagnosing food poisoning comprising the guide RNA of paragraph 1.

12. Use of the guide RNA of claim 1 for preparing a composition for diagnosing food poisoning.

13. A method for diagnosing food poisoning comprising the following steps: (a) a step of amplifying nucleic acid obtained from a sample; (b) a step of adding a guide RNA, endonuclease and reporter gene according to claim 1 to the amplification product and reacting them; (c) detecting a signal of the reporter gene; and (d) A step of diagnosing food poisoning when a signal of the reporter gene of step (c) is detected.